Primary Sclerosing Cholangitis Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Primary Sclerosing Cholangitis pipeline constitutes 14+ key companies continuously working towards developing 14+ Primary Sclerosing Cholangitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Primary Sclerosing Cholangitis Overview
Primary sclerosing cholangitis (PSC) is a chronic and progressive cholestatic liver disorder of unknown etiology. Inflammation, fibrosis, and stricturing of intrahepatic and/or extrahepatic biliary ducts characterize PSC. PSC is usually a progressive disorder that leads to complications of cholestasis and liver failure. Median survival from the time of diagnosis to death without liver transplantation is around 10 years.

"Primary Sclerosing Cholangitis Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Sclerosing Cholangitis Market.

The Primary Sclerosing Cholangitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Primary Sclerosing Cholangitis Pipeline Report: https://www.delveinsight.com/report-store/primary-sclerosing-cholangitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

• Companies across the globe are diligently working toward developing novel Primary Sclerosing Cholangitis treatment therapies with a considerable amount of success over the years. Primary Sclerosing Cholangitis Key players such as - Qing Bile Therapeutics, BiomX, Albireo Pharma, Cascade Pharmaceuticals, Chemomab Therapeutics, Mirum Pharmaceuticals, Pliant Therapeutics, Gilead Sciences, and others, are developing therapies for the Primary Sclerosing Cholangitis treatment
• Primary Sclerosing Cholangitis Emerging therapies such as - QBT-002, BX-003, A-3907, CS0159, CM 101, Volixibat, PLN-74809, Cilofexor, and others are expected to have a significant impact on the Primary Sclerosing Cholangitis market in the coming years.
• Gilead Sciences, Inc. and Phenex Pharmaceuticals AG, signed a definitive agreement under which Gilead acquired Phenex's Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH)

Primary Sclerosing Cholangitis Pipeline Therapeutics Assessment
• Primary Sclerosing Cholangitis Assessment by Product Type
• Primary Sclerosing Cholangitis By Stage and Product Type
• Primary Sclerosing Cholangitis Assessment by Route of Administration
• Primary Sclerosing Cholangitis By Stage and Route of Administration
• Primary Sclerosing Cholangitis Assessment by Molecule Type
• Primary Sclerosing Cholangitis by Stage and Molecule Type

DelveInsight's Primary Sclerosing Cholangitis Report covers around 14+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Primary Sclerosing Cholangitis Drugs Under Different Phases of Clinical Development Include:
• QBT-002: Qing Bile Therapeutics
• BX-003: BiomX
• A-3907: Albireo Pharma
• CS0159: Cascade Pharmaceuticals
• CM 101: Chemomab Therapeutics
• Volixibat: Mirum Pharmaceuticals
• PLN-74809: Pliant Therapeutics
• Cilofexor: Gilead Sciences

Get a Free Sample PDF Report to know more about Primary Sclerosing Cholangitis Pipeline Assessment- https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Primary Sclerosing Cholangitis Pipeline Analysis:
The Primary Sclerosing Cholangitis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Primary Sclerosing Cholangitis treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Sclerosing Cholangitis Treatment.
• Primary Sclerosing Cholangitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Primary Sclerosing Cholangitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Primary Sclerosing Cholangitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Primary Sclerosing Cholangitis product details are provided in the report. Download the Primary Sclerosing Cholangitis pipeline report to learn more about the emerging Primary Sclerosing Cholangitis therapies at:
https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Primary Sclerosing Cholangitis Pipeline Market Drivers
• Increasing prevalence of diseases associated with Primary Sclerosing Cholangitis such as liver cancer and inflammatory bowel disease
• Large number of Primary Sclerosing Cholangitis pipeline molecules

Primary Sclerosing Cholangitis Pipeline Market Barriers
• Withdrawal of molecules from late clinical stages
• Lack of skilled professionals or trained expertise

Scope of Primary Sclerosing Cholangitis Pipeline Drug Insight
• Coverage: Global
• Key Primary Sclerosing Cholangitis Companies: Qing Bile Therapeutics, BiomX, Albireo Pharma, Cascade Pharmaceuticals, Chemomab Therapeutics, Mirum Pharmaceuticals, Pliant Therapeutics, Gilead Sciences, and others
• Key Primary Sclerosing Cholangitis Therapies: QBT-002, BX-003, A-3907, CS0159, CM 101, Volixibat, PLN-74809, Cilofexor, and others
• Primary Sclerosing Cholangitis Therapeutic Assessment: Primary Sclerosing Cholangitis current marketed and Primary Sclerosing Cholangitis emerging therapies
• Primary Sclerosing Cholangitis Market Dynamics: Primary Sclerosing Cholangitis market drivers and Primary Sclerosing Cholangitis market barriers

Request for Sample PDF Report for Primary Sclerosing Cholangitis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Primary Sclerosing Cholangitis Report Introduction
2 Primary Sclerosing Cholangitis Executive Summary
3 Primary Sclerosing Cholangitis Overview
4 Primary Sclerosing Cholangitis- Analytical Perspective In-depth Commercial Assessment
5 Primary Sclerosing Cholangitis Pipeline Therapeutics
6 Primary Sclerosing Cholangitis Late Stage Products (Phase II/III)
7 Primary Sclerosing Cholangitis Mid Stage Products (Phase II)
8 Primary Sclerosing Cholangitis Early Stage Products (Phase I)
9 Primary Sclerosing Cholangitis Preclinical Stage Products
10 Primary Sclerosing Cholangitis Therapeutics Assessment
11 Primary Sclerosing Cholangitis Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Primary Sclerosing Cholangitis Key Companies
14 Primary Sclerosing Cholangitis Key Products
15 Primary Sclerosing Cholangitis Unmet Needs
16 Primary Sclerosing Cholangitis Market Drivers and Barriers
17 Primary Sclerosing Cholangitis Future Perspectives and Conclusion
18 Primary Sclerosing Cholangitis Analyst Views
19 Appendix
20 About DelveInsight

Download Sample PDF Report to know more about Primary Sclerosing Cholangitis drugs and therapies- https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:

Primary Sclerosing Cholangitis Market https://www.delveinsight.com/report-store/primary-sclerosing-cholangitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Primary Sclerosing Cholangitis-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Primary Sclerosing Cholangitis Epidemiology https://www.delveinsight.com/report-store/primary-sclerosing-cholangitis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Primary Sclerosing Cholangitis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"DelveInsight's 'Ventricular Assist Devices (VAD) Market Insight, Competitive Landscape and Market Forecast - 2027' report delivers an in-depth understanding of Ventricular Assist Devices and the historical and forecasted Ventricular Assist Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Vein Illumination Devices - Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Basal Cell Carcinoma (Basal Cell Epithelioma) Market
https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Basal Cell Carcinoma (Basal Cell Epithelioma) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Carcinoma (Basal Cell Epithelioma), historical and forecasted epidemiology as well as the Basal Cell Carcinoma (Basal Cell Epithelioma) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.